On February 28, 2024 Disruptive Pharma reported the company’s Board of Directors has, subject to approval at an extraordinary general meeting on April 2, 2024 has, subject to approval at an extraordinary general meeting on April 2, 2024, resolved to conduct a new share issue with preferential rights for the Company’s existing shareholders, which, if fully subscribed, will provide the Company with approximately SEK 35 million before issue costs (the "Rights Issue") (Press release, Disruptive Pharma, FEB 8, 2024, View Source [SID1234649945]). The purpose of the Rights Issue is primarily to finance development activities related to the Company’s first product candidate, DPH001.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!